Poor
Mostly Unaligned
Patient Risk:
Low
Summary
Most statements are not supported by the provided prescribing information excerpts (e.g., pricing, availability, pancreatitis counseling, adherence/QoL/cost-effectiveness, reduction of healthcare costs, and risk reduction for diabetes/heart disease). The only label-supported content present is the indication statement (diets/exercise, CV risk reduction, weight reduction/maintenance, and injection MASH; plus limitations of use with other semaglutide/GLP-1 products).
Category Scores
Accurate Statements
Use of WEGOVY (semaglutide) in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular (CV) events, reduce excess body weight and maintain weight reduction long term in adults/adolescents with obesity or overweight (with specified comorbidities), and (for injection) treat noncirrhotic MASH with moderate to advanced fibrosis in adults.
Supported by 1 INDICATIONS AND USAGE: injection indications (CV risk reduction in adults with established CV disease and obesity/overweight; weight reduction/maintenance in adults with obesity and in pediatric patients aged 12+ with obesity; adults with overweight with at least one weight-related comorbidity) and injection indication for noncirrhotic MASH with moderate to advanced fibrosis (F2 to F3) with accelerated approval language. Also consistent with tablet indications for adults (CV risk reduction and weight reduction/maintenance) and that these indications are in combination with reduced calorie diet and increased physical activity.
Unsupported Statements
Wegovy (semaglutide) is a prescription medication used to treat obesity and weight-related conditions.
The provided excerpts do not explicitly state 'prescription' or the generalized framing 'weight-related conditions'—they specify particular labeled indications and limitations; this broader description is not directly supported by the supplied text.
Wegovy is priced around $1,300 per month.
Pricing information is not present in the supplied prescribing information excerpts.
Wegovy is priced lower than other obesity medications on the market.
Comparative pricing is not provided in the supplied prescribing information.
Making Wegovy more affordable increases patient adherence to their treatment plans.
The supplied prescribing information excerpts do not discuss affordability/adherence relationships.
Increased adherence to Wegovy can lead to better health outcomes and reduced healthcare costs in the long run.
No affordability/adherence/long-term healthcare cost linkage is present in the supplied excerpts.
Wegovy has been shown to reduce healthcare costs associated with obesity, such as hospitalizations and surgeries.
The supplied excerpts do not provide health-economic outcomes (hospitalizations/surgeries/cost reductions).
Wegovy has been shown to be effective in helping patients achieve and maintain weight loss.
The supplied indication text supports weight reduction and weight maintenance in labeled populations, but the statement is phrased as a general effectiveness claim without tying to the specific labeled indication language in the excerpt; it is therefore treated as not directly supported by the provided text.
By reducing weight and improving overall health, Wegovy can reduce the risk of developing weight-related health issues, such as diabetes and heart disease.
The supplied excerpts do not state reductions in diabetes risk or prevention of heart disease beyond the labeled 'reduce the risk of major adverse cardiovascular (CV) events' indication.
Wegovy can help patients feel more confident and improve their overall quality of life.
No quality-of-life or confidence outcomes are included in the supplied excerpts.
Wegovy is available in all 50 states.
Geographic availability is not addressed in the supplied prescribing information.
Wegovy availability may vary depending on insurance coverage and other factors.
Insurance-dependent availability is not described in the supplied prescribing information excerpts.
Patients with a history of pancreatitis should consult with their doctor before using Wegovy.
The supplied excerpts mention acute pancreatitis observation and management (5.2) but do not include a 'history of pancreatitis' counseling instruction.
Wegovy has the potential to save patients money on their medication costs by offering a lower-cost option compared to other obesity medications.
No medication cost comparisons or lower-cost statements are present in the supplied excerpts.
Wegovy can save patients money by reducing healthcare costs associated with obesity.
No patient cost savings or healthcare cost reduction claims are present in the supplied excerpts.
Contradictions
Important Omissions
If making safety statements, the label excerpt provided includes specific contraindications (MTC/MEN2; serious hypersensitivity to semaglutide/excipients) and a specific warnings-precautions section on acute pancreatitis (observe after initiation; discontinue if suspected). None of the non-indication safety statements provided in the claims accurately reflect these specific label elements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clearly label-grounded content is the indication statement. The remaining claims are mainly economic/access/psychosocial generalizations or unsupported safety counseling (pancreatitis history) not directly supported by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unaligned
Primary Issue
Multiple claims (pricing/availability/adherence/quality of life/healthcare cost savings and specific pancreatitis history counseling) are not supported by the supplied FDA label excerpts.
Suggested Improvement
Limit claims to the exact labeled indications and the provided label warning/contraindication content (e.g., contraindications and acute pancreatitis observation/discontinuation guidance) and remove or qualify all pricing, geographic availability, adherence/QoL, and healthcare-cost reduction statements unless supported by the supplied label text.